ATE496932T1 - Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10 - Google Patents

Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10

Info

Publication number
ATE496932T1
ATE496932T1 AT02718923T AT02718923T ATE496932T1 AT E496932 T1 ATE496932 T1 AT E496932T1 AT 02718923 T AT02718923 T AT 02718923T AT 02718923 T AT02718923 T AT 02718923T AT E496932 T1 ATE496932 T1 AT E496932T1
Authority
AT
Austria
Prior art keywords
ccr5
antibody
chemokine receptor
protein chemokine
hdgnr10
Prior art date
Application number
AT02718923T
Other languages
English (en)
Inventor
Viktor Roschke
Craig Rosen
Steven Ruben
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/779,880 external-priority patent/US20020061834A1/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority claimed from PCT/US2002/003634 external-priority patent/WO2002064612A2/en
Application granted granted Critical
Publication of ATE496932T1 publication Critical patent/ATE496932T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02718923T 2001-02-09 2002-02-08 Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10 ATE496932T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/779,880 US20020061834A1 (en) 2000-02-09 2001-02-09 Human G-protein Chemokine receptor (CCR5) HDGNR10
PCT/US2001/004153 WO2001058916A2 (en) 2000-02-09 2001-02-09 Antibodies to ccr5
US29725701P 2001-06-12 2001-06-12
US31045801P 2001-08-08 2001-08-08
US32844701P 2001-10-12 2001-10-12
US34172501P 2001-12-21 2001-12-21
PCT/US2002/003634 WO2002064612A2 (en) 2001-02-09 2002-02-08 Human g-protein chemokine receptor (ccr5) hdgnr10

Publications (1)

Publication Number Publication Date
ATE496932T1 true ATE496932T1 (de) 2011-02-15

Family

ID=46150070

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718923T ATE496932T1 (de) 2001-02-09 2002-02-08 Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10

Country Status (5)

Country Link
KR (1) KR20030081437A (de)
AT (1) ATE496932T1 (de)
AU (1) AU2008209670A1 (de)
MX (1) MXPA03007186A (de)
NZ (1) NZ527126A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6138815B2 (ja) * 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ, インコーポレイテッド 補体経路およびvegf経路に対するタンパク質インヒビターおよびそれらの使用方法

Also Published As

Publication number Publication date
MXPA03007186A (es) 2005-07-01
NZ527126A (en) 2007-04-27
KR20030081437A (ko) 2003-10-17
AU2008209670A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
CA2430135A1 (en) Recombinant anti-cd30 antibodies and uses thereof
US11753463B2 (en) Therapeutic targeting of non-cellular structures
CA2213833A1 (en) Vascular endothelial cell growth factor antagonists
Ortaldo et al. Mediation of mouse natural cytotoxic activity by tumour necrosis factor
US20090123456A1 (en) Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
JP2021519089A (ja) 二官能性タンパク質およびその作製
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP1798242A3 (de) Anti-IGF-IF-Antikörper und ihre Anwendungen
US9394362B2 (en) IL-21 antibodies and methods of making or using the antibodies
JP2005506035A5 (de)
NZ515464A (en) Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
MXPA05007843A (es) Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
BRPI0612273B1 (pt) anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição
RU94045826A (ru) Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i
TW202132332A (zh) IL—2Rβγc結合化合物
JP2018535948A5 (de)
CN113574071B (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
KR20200040881A (ko) 항-pacap 항체
Döring et al. Identification and characterization of a TNFα antagonist derived from a monoclonal antibody
Abe et al. Role of 55-and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
RU99120076A (ru) Гамма-1 и гамма-3 моноклональные антитела к cd23 человека и их использование для лечебных целей
Yoshino Effect of a monoclonal antibody against interleukin‐4 on collagen‐induced arthritis in mice
ES2222625T3 (es) Peptido t y peptidos asociados destinados al tratamiento de la inflamacion incluyendo la esclerosis multiple.
CN101626785A (zh) 神经延长促进剂及延长抑制剂